MEDICAL SERVICES

Languages

  • English

EDUCATION

Undergraduate Degree

Neuroscience
  • Amherst College , 1993

Graduate Degree

PhD, Molecular Basis of Disease
  • Mount Sinai Medical School , 2002

Medical School

  • Mount Sinai Medical School , 2002 , New York , NY

Internship

  • Mount Sinai Medical School , 2003 , New York , NY

Residency

Anatomic Pathology
  • Brigham and Women's Hospital , 2005 , Boston , MA

Fellowship

Neuropathology
  • Brigham and Women's Hospital , 2007 , Boston , MA

CERTIFICATIONS

  • American Board of Pathology, Anatomic Neuropathology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 Jan 05; 24(1):101-113. View abstract
  2. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 Jan 05; 24(1):64-77. View abstract
  3. Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data. IEEE Trans Vis Comput Graph. 2022 01; 28(1):259-269. View abstract
  4. Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2021 Dec 08. View abstract
  5. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nat Methods. 2021 Nov 25. View abstract
  6. Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data. Nat Biomed Eng. 2021 Nov 08. View abstract
  7. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell. 2021 09 16; 184(19):4996-5014.e26. View abstract
  8. A Molecularly Integrated Grade for Meningioma. Neuro Oncol. 2021 Sep 11. View abstract
  9. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. NPJ Breast Cancer. 2021 Sep 09; 7(1):116. View abstract
  10. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021 09 02; 184(18):4753-4771.e27. View abstract
  11. Prognostication for meningiomas: H3K27me3 to the rescue? Neuro Oncol. 2021 08 02; 23(8):1218-1219. View abstract
  12. Skull Base Tumors: Neuropathology and Clinical implications. Neurosurgery. 2021 Jun 23. View abstract
  13. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 06; 11(6):1508-1523. View abstract
  14. HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clin Cancer Res. 2021 03 15; 27(6):1706-1719. View abstract
  15. Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathol Commun. 2021 01 06; 9(1):8. View abstract
  16. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 Jan; 2(1):66-82. View abstract
  17. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 10 21; 8(1):171. View abstract
  18. Minerva: a light-weight, narrative image browser for multiplexed tissue images. J Open Source Softw. 2020; 5(54). View abstract
  19. SYLARAS: A Platform for the Statistical Analysis and Visual Display of Systemic Immunoprofiling Data and Its Application to Glioblastoma. Cell Syst. 2020 09 23; 11(3):272-285.e9. View abstract
  20. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543. View abstract
  21. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. 2020 07; 140(1):89-93. View abstract
  22. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020 04 16; 181(2):236-249. View abstract
  23. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523. View abstract
  24. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell. 2020 05 11; 37(5):705-719.e6. View abstract
  25. Correction to: An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020 Apr; 139(4):667. View abstract
  26. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377. View abstract
  27. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459. View abstract
  28. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020 08; 33(8):1475-1481. View abstract
  29. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020; 4:79-90. View abstract
  30. HSF1 phase transition mediates stress adaptation and cell fate decisions. Nat Cell Biol. 2020 02; 22(2):151-158. View abstract
  31. Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. Sci Data. 2019 12 17; 6(1):323. View abstract
  32. Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma. Cancer Res. 2020 03 15; 80(6):1258-1267. View abstract
  33. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat Protoc. 2019 10; 14(10):2900-2930. View abstract
  34. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2. View abstract
  35. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019 09 01; 125(17):2910-2914. View abstract
  36. Rapid MALDI mass spectrometry imaging for surgical pathology. NPJ Precis Oncol. 2019; 3:17. View abstract
  37. Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul; 15(7):757. View abstract
  38. Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clin Cancer Res. 2019 11 01; 25(21):6392-6405. View abstract
  39. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020 04; 139(4):643-665. View abstract
  40. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400. View abstract
  41. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 07; 15(7):681-689. View abstract
  42. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. View abstract
  43. The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathol. 2019 02; 137(2):307-319. View abstract
  44. New molecular targets in meningiomas: the present and the future. Curr Opin Neurol. 2018 12; 31(6):740-746. View abstract
  45. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst. 2018 12 01; 110(12):1328-1341. View abstract
  46. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018. View abstract
  47. Updates in prognostic markers for gliomas. Neuro Oncol. 2018 11 09; 20(suppl_7):vii17-vii26. View abstract
  48. Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. J Neuropathol Exp Neurol. 2018 10 01; 77(10):877-882. View abstract
  49. Meningioma transcription factors link cell lineage with systemic metabolic cues. Neuro Oncol. 2018 09 03; 20(10):1331-1343. View abstract
  50. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. J Neurooncol. 2018 Nov; 140(2):269-279. View abstract
  51. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792. View abstract
  52. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018 07 11; 7. View abstract
  53. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018 07 05; 20(8):1101-1112. View abstract
  54. Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:148-157. View abstract
  55. Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. Ann Oncol. 2018 03 01; 29(3):537-540. View abstract
  56. A case of molecularly profiled extraneural medulloblastoma metastases in a child. BMC Med Genet. 2018 01 17; 19(1):10. View abstract
  57. Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. Digit J Ophthalmol. 2017; 23(4):22-26. View abstract
  58. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908. View abstract
  59. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017 Oct 19; 19(11):1447-1456. View abstract
  60. Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. Am J Surg Pathol. 2017 Oct; 41(10):1410-1421. View abstract
  61. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Cell Commun Signal. 2017 09 18; 15(1):34. View abstract
  62. Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2:26. View abstract
  63. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View abstract
  64. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291. View abstract
  65. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2. View abstract
  66. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545. View abstract
  67. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5. View abstract
  68. Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report. Open Forum Infect Dis. 2017; 4(1):ofx021. View abstract
  69. Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage. Adv Cancer Res. 2017; 134:257-282. View abstract
  70. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A. 2017 01 10; 114(2):382-387. View abstract
  71. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics. Neurosurg Focus. 2016 Dec; 41(6):E3. View abstract
  72. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Neurosurg Focus. 2016 Dec; 41(6):E2. View abstract
  73. Susan Lindquist (1949-2016). Science. 2016 Nov 25; 354(6315):974. View abstract
  74. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg. 2017 08; 127(2):438-444. View abstract
  75. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576. View abstract
  76. Treatment of brain metastases in the modern genomic era. Pharmacol Ther. 2017 02; 170:64-72. View abstract
  77. Landscape of Genomic Alterations in Pituitary Adenomas. Clin Cancer Res. 2017 Apr 01; 23(7):1841-1851. View abstract
  78. Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. Mod Pathol. 2016 12; 29(12):1446-1459. View abstract
  79. Checkpoint inhibition in meningiomas. Immunotherapy. 2016 06; 8(6):721-31. View abstract
  80. SU-D-207B-02: Early Grade Classification in Meningioma Patients Combining Radiomics and Semantics Data. Med Phys. 2016 Jun; 43(6):3348-3349. View abstract
  81. Label-Free Neurosurgical Pathology with Stimulated Raman Imaging. Cancer Res. 2016 06 15; 76(12):3451-62. View abstract
  82. Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol. 2016 Mar; 238(4):584-97. View abstract
  83. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82. View abstract
  84. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55. View abstract
  85. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016 09; 125(3):525-35. View abstract
  86. Case-Based Review: meningioma. Neurooncol Pract. 2016 Jun; 3(2):120-134. View abstract
  87. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol. 2016 Apr; 174(4):R139-44. View abstract
  88. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2016 Feb; 108(2). View abstract
  89. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. View abstract
  90. Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. Elife. 2015 Sep 01; 4. View abstract
  91. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74. View abstract
  92. MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation. Proc Natl Acad Sci U S A. 2015 Aug 11; 112(32):9978-83. View abstract
  93. Profiling of adrenocorticotropic hormone and arginine vasopressin in human pituitary gland and tumor thin tissue sections using droplet-based liquid-microjunction surface-sampling-HPLC-ESI-MS-MS. Anal Bioanal Chem. 2015 Aug; 407(20):5989-98. View abstract
  94. Intraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric Study. World Neurosurg. 2015 Aug; 84(2):528-36. View abstract
  95. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96. View abstract
  96. ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet. 2015 Jun; 208(6):345-50. View abstract
  97. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16. View abstract
  98. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55. View abstract
  99. Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making. Int J Mass Spectrom. 2015 Feb 01; 377:690-698. View abstract
  100. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167. View abstract
  101. HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18297-302. View abstract
  102. Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Mod Pathol. 2015 Apr; 28(4):596-606. View abstract
  103. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606. View abstract
  104. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92. View abstract
  105. Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. Expert Rev Anticancer Ther. 2014 Dec; 14(12):1385-9. View abstract
  106. Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15184-9. View abstract
  107. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 01; 34(10):e87-9. View abstract
  108. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014 Jul 31; 158(3):564-78. View abstract
  109. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11121-6. View abstract
  110. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53. View abstract
  111. Artifacts to avoid while taking advantage of top-down mass spectrometry based detection of protein S-thiolation. Proteomics. 2014 May; 14(10):1152-7. View abstract
  112. Structure-activity relationships for withanolides as inducers of the cellular heat-shock response. J Med Chem. 2014 Apr 10; 57(7):2851-63. View abstract
  113. Atypical presentation of cerebral schistosomiasis four years after exposure to Schistosoma mansoni. Epilepsy Behav Case Rep. 2014; 2:80-5. View abstract
  114. The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection. PLoS Pathog. 2014 Feb; 10(2):e1003904. View abstract
  115. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest. 2014 Feb; 124(2):859-70. View abstract
  116. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. View abstract
  117. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5. View abstract
  118. Mass spectrometry imaging as a tool for surgical decision-making. J Mass Spectrom. 2013 Nov; 48(11):1178-87. View abstract
  119. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Sci Rep. 2013 Oct 04; 3:2859. View abstract
  120. Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med. 2013 Sep 04; 5(201):201ra119. View abstract
  121. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143):1238303. View abstract
  122. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol. 2013 Jul; 31(7):630-7. View abstract
  123. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View abstract
  124. Eastern equine encephalitis in children, Massachusetts and New Hampshire,USA, 1970-2010. Emerg Infect Dis. 2013 Feb; 19(2):194-201; quiz 352. View abstract
  125. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9. View abstract
  126. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1611-6. View abstract
  127. Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr Mol Med. 2012 Nov 01; 12(9):1108-24. View abstract
  128. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest. 2012 Oct; 122(10):3742-54. View abstract
  129. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell. 2012 Aug 03; 150(3):549-62. View abstract
  130. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881. View abstract
  131. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res. 2012 Feb 01; 72(3):645-54. View abstract
  132. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol. 2012 Feb 17; 7(2):340-9. View abstract
  133. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A. 2011 Nov 08; 108(45):18378-83. View abstract
  134. Desorption electrospray ionization then MALDI mass spectrometry imaging of lipid and protein distributions in single tissue sections. Anal Chem. 2011 Nov 15; 83(22):8366-71. View abstract
  135. Relapsing tumefactive lesion in an adult with medulloblastoma previously treated with chemoradiotherapy and stem cell transplant. Pathol Oncol Res. 2012 Apr; 18(2):539-43. View abstract
  136. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn. 2011 Nov; 13(6):669-77. View abstract
  137. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948. View abstract
  138. Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. J Mol Diagn. 2011 Mar; 13(2):220-32. View abstract
  139. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30. View abstract
  140. Novel MPZ mutations and congenital hypomyelinating neuropathy. Neuromuscul Disord. 2010 Nov; 20(11):725-9. View abstract
  141. Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci U S A. 2010 Oct 05; 107(40):17385-90. View abstract
  142. Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res. 2010 May 16; 2(3):309-15. View abstract
  143. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell. 2010 May 28; 141(5):872-83. View abstract
  144. CRX is a diagnostic marker of retinal and pineal lineage tumors. PLoS One. 2009 Nov 20; 4(11):e7932. View abstract
  145. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887. View abstract
  146. Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol. 2009 Sep; 5(9):655-63. View abstract
  147. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7. View abstract
  148. Mycosis fungoides with leptomeningeal involvement. J Clin Oncol. 2007 Dec 10; 25(35):5658-61. View abstract
  149. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007 Jun; 31(6):836-45. View abstract
  150. Post-irradiation meningioma with sarcoidosis. J Neurooncol. 2007 May; 82(3):271-2. View abstract
  151. Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. J Neurooncol. 2007 Jan; 81(1):49-51. View abstract
  152. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol. 2006 Dec; 30(12):1613-8. View abstract
  153. Intramedullary neuroma of the cervicomedullary junction. Case report. J Neurosurg Spine. 2006 Oct; 5(4):362-6. View abstract
  154. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005 Jul; 1(1):72-80. View abstract
  155. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004 Oct 01; 64(19):6854-7. View abstract
  156. FokI requires two specific DNA sites for cleavage. J Mol Biol. 2001 May 25; 309(1):69-78. View abstract
  157. G-protein signaling through tubby proteins. Science. 2001 Jun 15; 292(5524):2041-50. View abstract
  158. Recombinase activating gene enzymes of lymphocytes. Curr Opin Hematol. 2001 Jan; 8(1):41-6. View abstract
  159. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001 Jan 01; 97(1):81-8. View abstract
  160. N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Proc Natl Acad Sci U S A. 2000 Dec 19; 97(26):14572-7. View abstract
  161. The genetic and biochemical basis of Omenn syndrome. Immunol Rev. 2000 Dec; 178:64-74. View abstract
  162. Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies. Mol Cell Biol. 2000 Aug; 20(15):5653-64. View abstract
  163. Definition of minimal domains of interaction within the recombination-activating genes 1 and 2 recombinase complex. J Immunol. 2000 Jun 01; 164(11):5826-32. View abstract
  164. Implication of tubby proteins as transcription factors by structure-based functional analysis. Science. 1999 Dec 10; 286(5447):2119-25. View abstract
  165. The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombination. Mol Cell. 1999 Dec; 4(6):935-47. View abstract
  166. The RAG1 homeodomain recruits HMG1 and HMG2 to facilitate recombination signal sequence binding and to enhance the intrinsic DNA-bending activity of RAG1-RAG2. Mol Cell Biol. 1999 Oct; 19(10):6532-42. View abstract
  167. Molecular cloning and characterization of a mouse homolog of bacterial ClpX, a novel mammalian class II member of the Hsp100/Clp chaperone family. J Biol Chem. 1999 Jun 04; 274(23):16311-9. View abstract
  168. Omenn syndrome: a disorder of Rag1 and Rag2 genes. J Clin Immunol. 1999 Mar; 19(2):87-97. View abstract
  169. The effect of Me2+ cofactors at the initial stages of V(D)J recombination. J Biol Chem. 1998 Jun 26; 273(26):16325-31. View abstract
  170. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998 May 29; 93(5):885-96. View abstract
  171. The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination. Cell . 1996; 87(2):263-276. View abstract
  172. Studies on the Physiology and Plasticity of the Binocular Visual Pathway in the Frog, Rana pipiens. 1993. View abstract